Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of Response Evaluation Criteria in Solid Tumors and tumor markers

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 4, 2015, Pages 726-732

  Miyaki, Daisuke ^a   Kawaoka, Tomokazu ^a   Aikata, Hiroshi ^a   Kan, Hiromi ^a   Fujino, Hatsue ^a   Fukuhara, Takayuki ^a   Kobayashi, Tomoki ^a   Naeshiro, Noriaki ^a   Honda, Yohji ^a   Tsuge, Masataka ^a   Hiramatsu, Akira ^a   Imamura, Michio ^a   Hyogo, Hideyuki ^a   Kawakami, Yoshiiku ^a   Yoshimatsu, Rika ^b   Yamagami, Takuji ^b   Awai, Kazuo ^b   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Early response; Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; RECIST; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; CISPLATIN; DECARBOXYPROTHROMBIN; FLUOROURACIL; RECOMBINANT ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CHILD PUGH SCORE; CORRELATION ANALYSIS; FEMALE; FEVER; FOLLOW UP; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT RESPONSE; VERY ELDERLY; BLOOD; CARCINOMA, HEPATOCELLULAR; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; BIOMARKERS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; PROTHROMBIN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84924786984     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12821     Document Type: Article

References (25)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010; 127: 2893-2917.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006; 24: 2137-2150.
3. Livraghi T, Giorgio A, Marin G etal. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101-108.
4. Kamada K, Kitamoto M, Aikata H etal. Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am. J. Surg. 2002; 184: 284-290.
5. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655-661.
6. Goldstein HM, Wallace S, Anderson JH, Bree RL, Gianturco C. Transcatheter occlusion of abdominal tumors. Radiology 1976; 120: 539-545.
7. Chuang VP, Wallace S. Hepatic artery embolization in the treatment of hepatic neoplasms. Radiology 1981; 140: 51-58.
8. Stehlin JS Jr, de Ipolyi PD, Greeff PJ, McGaff CJ Jr, Davis BR, McNary L. Treatment of cancer of the liver. Twenty years' experience with infusion and resection in 414 patients. Ann. Surg. 1988; 208: 23-35.
9. Doci R, Bignami P, Bozzetti F etal. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 1988; 61: 1983-1987.
10. Ando E, Tanaka M, Yamashita F etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-595.
11. Obi S, Yoshida H, Toune R etal. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-1997.
12. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-390.
13. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
14. Uka K, Aikata H, Takaki S etal. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J. Gastroenterol. 2007; 42: 845-853.
15. Uka K, Aikata H, Takaki S etal. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int. 2007; 27: 1209-1216.
16. Katamura Y, Aikata H, Takaki S etal. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J. Gastroenterol. 2009; 44: 492-502.
17. Miyaki D, Aikata H, Honda Y etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. J. Gastroenterol. Hepatol. 2012; 27: 1850-1857.
18. Eisenhauer EA, Therasse P, Bogaerts J etal. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009; 45: 228-247.
19. Memon K, Kulik L, Lewandowski RJ etal. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J. Hepatol. 2012; 56: 1112-1120.
20. Tsai MC, Wang JH, Hung CH etal. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J. Gastroenterol. Hepatol. 2010; 25: 605-612.
21. Nagaoka S, Yatsuhashi H, Hamada H etal. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 2003; 98: 2671-2677.
22. Kobayashi M, Ikeda K, Kawamura Y etal. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009; 115: 571-580.
23. Miyaki D, Aikata H, Kan H etal. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. J. Gastroenterol. Hepatol. 2013; 28: 1834-1841.
24. Llovet JM, Pena CE, Lathia CD etal. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 2012; 18: 2290-2300.
25. Niizeki T, Sumie S, Torimura T etal. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J. Gastroenterol. 2012; 47: 686-695.